Skip to content
Screener

Arvinas ARVN Cash & Equivalents

Cash & Equivalents at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$68.65M-19.4%
LON
LeonaBio, Inc.LONA
$32.83M+24.3%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$124.48M-62.9%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$90.1M+29.8%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$9.78M+750%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$62.1M+24.5%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$572.13M+18.3%
Enterprise value$493.43M+30.3%
P/S6.4×+5.1×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Arvinas’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 5:18 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033669
(dollars in millions)For the Three Months Ended March 31, 2026For the Three Months Ended March 31, 2025
Cash flows from financing activities:
Repayments of long-term debt(0.1)(0.1)
Net cash used in financing activities(0.1)(0.1)
Net decrease in cash and cash equivalents(55.6)(19.5)
Cash and cash equivalents, beginning of the period142.9100.5
Cash and cash equivalents, end of the period$87.3$81.0
Supplemental disclosure of cash flow information:
Purchases of property, equipment and leasehold improvements unpaid at period end$0.1

Item 1. Financial Statements (Unaudited)

FAQ

What is Arvinas's cash & equivalents?
Arvinas (ARVN) reported cash & equivalents of $87.3M in Q1 2026.
How has Arvinas's cash & equivalents changed year-over-year?
Arvinas's cash & equivalents increased by 7.8% year-over-year, from $81M to $87.3M.
What is the long-term trend for Arvinas's cash & equivalents?
Over 5 years (2020 to 2025), Arvinas's cash & equivalents has grown at a -24.7% compound annual growth rate (CAGR), from $588.4M to $142.9M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Arvinas's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude